Clinical impact of tumour burden on the efficacy of PD‐1/PD‐L1 inhibitors plus chemotherapy in non‐small‐cell lung cancer

BACKGROUND: Programmed cell death 1 (PD‐1)/programmed cell death ligand (PD‐L1) inhibitors plus chemotherapy (ICI + Chemo) is the standard treatment for advanced non‐small‐cell lung cancer (NSCLC). However, the impact of tumour burden on the efficacy of ICI + Chemo remains unknown. METHODS: We retro...

Descripción completa

Detalles Bibliográficos
Autores principales: Miyawaki, Taichi, Kenmotsu, Hirotsugu, Doshita, Kosei, Kodama, Hiroaki, Nishioka, Naoya, Iida, Yuko, Miyawaki, Eriko, Mamesaya, Nobuaki, Kobayashi, Haruki, Omori, Shota, Ko, Ryo, Wakuda, Kazushige, Ono, Akira, Naito, Tateaki, Murakami, Haruyasu, Mori, Keita, Harada, Hideyuki, Endo, Masahiro, Takahashi, Kazuhisa, Takahashi, Toshiaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883568/
https://www.ncbi.nlm.nih.gov/pubmed/35848053
http://dx.doi.org/10.1002/cam4.5035

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883568/
https://www.ncbi.nlm.nih.gov/pubmed/35848053
http://dx.doi.org/10.1002/cam4.5035

Ejemplares similares